Konskie

Researchers are evaluating the safety and effectiveness of different doses of morphine administered during spinal anesthesia to manage pain after total hip replacement surgery. The study focuses on balancing the benefits of morphines long-lasting pain relief with the risks, especially respiratory depression, which requires precise dosing. This Phase 4 trial is sponsored by the Medical University of Silesia and investigates doses of 50 mcg, 100 mcg, and 150 mcg of morphine given intrathecally alongside bupivacaine. Patients receive spinal anesthesia with 15 mg of 0.5% bupivacaine through a carefully performed spinal puncture. Along with bupivacaine, they are randomly assigned to one of three groups receiving different doses of morphine intrathecally 50 mcg, 100 mcg, or 150 mcg. Postoperative pain management includes scheduled doses of paracetamol, dexketoprofen, and metamizole, as well as patient-controlled analgesia PCA with oxycodone administered via a syringe pump. Continuous vital signs monitoring occurs for 48 hours after surgery. Participants will be observed for 48 hours after surgery to assess pain relief and safety outcomes. Researchers will measure analgesic efficacy, patient satisfaction, time to additional analgesia, total oxycodone use, and length of hospital stay up to one week. Continuous monitoring and questionnaires will help evaluate the safety profile and patient recovery. The trial enrollment includes adults aged 18 to 75 years undergoing total hip replacement surgery.